impact of chromosome 1 abnormalities among pts with ndmm: subgroup analysis from the endurance trial
Published 2 years ago • 568 plays • Length 7:58Download video MP4
Download video MP3
Similar videos
-
1:51
why should chromosome 1 abnormalities be assessed in all patients with mm?
-
3:23
what are the results from the endurance trial that compares krd to vrd in newly diagnosed patients?
-
11:06
krd vs vrd as induction therapy in newly diagnosed high-risk multiple myeloma
-
3:19:22
patient & family webinar: from best of ash 2021 to 2022 covid-19 guidance
-
4:07
why is it important for #myeloma patients to know the cytogenetic abnormalities of their cancer?
-
1:44
structural variants in multiple myeloma: impact on outcomes & potential drug targets
-
0:38
spider-man: doc ock’s tentacle trap - lego marvel super heroes - 76059 - product animation
-
4:52
patient segmentation for targeted therapy in myeloma
-
3:59
single cell analysis | gareth morgan, md, phd | ims 2022
-
37:46
current and future directions for novel therapy for multiple myeloma: paul g. richardson, md
-
2:30
using biomarkers to identify molecular lesions and monitor response to treatment in multiple myeloma
-
0:26
lego bricks classification on embedded device with neural accelerators
-
47:16
cure is not enough improving quality of survival in neuroblastoma
-
0:50
lego ultra agents - intel a
-
4:10
lucient larva moc
-
18:39
sequencing the genome in myeloma: pitfalls and opportunities in the clinic
-
1:05:25
post asco eha 2020 webinar